Mark For: ARTEMIS® trademark registration is intended to cover the categories of
Research | OneLook Acronym Finder |
Serial Number | 86880860 |
Registration Number | 5897433 |
Mark Literal Elements | ARTEMIS |
Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
Mark Type | Trademark |
Current Location | PUBLICATION AND ISSUE SECTION 2019-09-23 |
Basis | 1(a) |
Class Status | ACTIVE |
Primary US Classes |
|
Primary International Class |
|
Filed Use | No |
Current Use | Yes |
Intent To Use | No |
Filed ITU | Yes |
44D Filed | No |
44E Current | No |
66A Current | No |
Current Basis | No |
No Basis | No |
Attorney Name | Jennifer Lee Taylor |
Attorney Docket Number | 750046001000 |
Law Office Assigned | M50 |
Employee Name | KEAM, ALEX S |
2016-01-20 | Application Filed |
2017-08-15 | Published |
2017-08-15 | Published for Opposition |
2019-07-31 | Date of First Use |
2019-07-31 | Date of Use In Commerce |
2019-09-23 | Location: PUBLICATION AND ISSUE SECTION |
2019-10-29 | Status: Live/Registered |
2019-10-29 | Status: Registered. The registration date is used to determine when post-registration maintenance documents are due. |
2019-10-29 | Trademark Registered |
2019-10-29 | Transaction Date |
2024-10-29 | Maintenance Early File Date |
2025-10-29 | Maintenance On Time Date |
2026-04-29 | Maintenance Late Fee Date |
Party: | EUREKA THERAPEUTICS, INC. |
Address | 5858 HORTON STREET, SUITE 170 EMERYVILLE, CALIFORNIA UNITED STATES 94608 |
Legal Entity Type | Corporation |
Legal Entity State | DELAWARE |
Party: | Eureka Therapeutics, Inc. |
Address | 5858 Horton Street, Suite 362 Emeryville CA 94608 |
Legal Entity Type | |
Legal Entity State | CA |
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
Type Code | Type |
---|---|
GS0051 | Biologics, namely, chimeric immune cell antigen receptors, namely, engineered immune cells made from an individual patient's immune cells and proprietary DNA, for therapeutic use for the treatment of cancers, for the treatment of proliferative cell diseases, and in transplantation |
GS0051 | Biologics, namely, chimeric immune cell antigen receptors, namely, engineered immune cells made from an individual patient's immune cells and proprietary DNA, for therapeutic use for the treatment of cancers, for the treatment of proliferative cell diseases, and in transplantation |
Description | Date |
---|---|
Trademark Assignment 7257-0573 [5 Pages] | 2021-04-15 |
Description | Date | Proceeding Number |
---|---|---|
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2021-04-29 | |
REGISTERED-PRINCIPAL REGISTER | 2019-10-29 | |
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2019-09-24 | |
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2019-09-23 | |
STATEMENT OF USE PROCESSING COMPLETE | 2019-09-21 | |
CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2019-09-21 | |
USE AMENDMENT FILED | 2019-08-30 | |
TEAS STATEMENT OF USE RECEIVED | 2019-08-30 | |
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-03-28 | |
SOU TEAS EXTENSION RECEIVED | 2019-03-26 | |
SOU EXTENSION 3 GRANTED | 2019-03-26 | |
SOU EXTENSION 3 FILED | 2019-03-26 | |
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-08-31 | |
SOU TEAS EXTENSION RECEIVED | 2018-08-29 | |
SOU EXTENSION 2 GRANTED | 2018-08-29 | |
SOU EXTENSION 2 FILED | 2018-08-29 | |
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-03-29 | |
SOU TEAS EXTENSION RECEIVED | 2018-03-27 | |
SOU EXTENSION 1 GRANTED | 2018-03-27 | |
SOU EXTENSION 1 FILED | 2018-03-27 | |
NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2017-10-10 | |
PUBLISHED FOR OPPOSITION | 2017-08-15 | |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2017-08-15 | |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2017-07-26 | |
EXPARTE APPEAL TERMINATED | 2017-07-01 | 880860 |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2017-07-01 | |
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2017-06-20 | |
EXAMINERS AMENDMENT E-MAILED | 2017-06-20 | |
EXAMINERS AMENDMENT -WRITTEN | 2017-06-20 | |
EXAMINER'S AMENDMENT ENTERED | 2017-06-20 | |
ASSIGNED TO LIE | 2017-06-20 | |
JURISDICTION RESTORED TO EXAMINING ATTORNEY | 2017-06-02 | 880860 |
EXPARTE APPEAL RECEIVED AT TTAB | 2017-06-02 | |
EX PARTE APPEAL-INSTITUTED | 2017-06-02 | 880860 |
TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2017-06-01 | |
NOTIFICATION OF FINAL REFUSAL EMAILED | 2016-12-01 | |
FINAL REFUSAL WRITTEN | 2016-12-01 | |
FINAL REFUSAL E-MAILED | 2016-12-01 | |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2016-11-12 | |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2016-11-11 | |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2016-11-11 | |
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2016-05-11 | |
NON-FINAL ACTION WRITTEN | 2016-05-11 | |
NON-FINAL ACTION E-MAILED | 2016-05-11 | |
ASSIGNED TO EXAMINER | 2016-05-05 | |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | 2016-01-25 | |
NEW APPLICATION ENTERED | 2016-01-23 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.